Physician profile
Phoebe Sun
NPI 1144222951
$990.09
in general payments reported to CMS, 2019-2025
22 companies · $159 in 2025
The $159 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $415 · 2020: $66.00 · 2021: $81.15 · 2022: $86.76 · 2023: $55.02 · 2024: $127 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $341.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $285.77 | 2019-2022 | |
| Astellas Pharma US INC | $229.31 | 2019-2024 | Veozah, Myrbetriq |
| Optumhealth Care Solutions, LLC | $61.10 | 2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Baxter Healthcare | $59.28 | 2025 | Perclot |
| Mayne Pharma Commercial LLC | $46.75 | 2021-2024 | |
| Allergan, INC. | $38.04 | 2019 | |
| Biogen, INC. | $28.86 | 2024 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $26.18 | 2019-2020 | |
| Smith+Nephew, INC. | $24.48 | 2025 | Pico 14, Pico 7 |
| Organon LLC | $20.85 | 2024 | |
| Sumitomo Pharma America, INC. | $20.82 | 2024 | Myfembree |
| Exeltis, USA INC. | $20.08 | 2024 | Slynd |
| Roche Diagnostics Corporation | $17.80 | 2019 | |
| Novo Nordisk INC | $17.60 | 2020 | |
| Amgen INC. | $15.79 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $14.28 | 2025 | |
| Merck Sharp & Dohme LLC | $14.13 | 2019 | |
| Novum Pharma, LLC | $13.00 | 2019 | |
| Avanos Medical | $12.59 | 2019 | |
| Pfizer INC. | $12.38 | 2019 | |
| Davol INC. | $11.00 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phoebe Sun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.